REG - GENinCode PLC - Result of GM and Total Voting Rights

GenincodeAnnouncement

09/01/2024 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240109:nRSI1308Za&default-theme=true

RNS Number : 1308Z  GENinCode PLC  09 January 2024

9 January 2024

 

 

 

GENinCode Plc

("GENinCode" or the "Company")

 

Result of General Meeting, Issue of Equity and Total Voting Rights

 

GENinCode plc (AIM: GENI), the polygenics company focused on the prevention of
cardiovascular disease ("CVD"), announces that all resolutions put to
Shareholders at the General Meeting held earlier today in connection with the
placing, subscription and retail offer announced by the Company on 21 December
2023 were duly passed.

 

 

 Resolution                                                                            For                       Against                  Withheld         Total votes cast
                                                                                       Number of votes  %        Number of votes  %       Number of votes
 1       Ordinary resolution to authorise the directors to allot shares

                                                                                       31,947,121       99.99%   2,846            0.01%   7,085            31,949,967

 2       Special resolution to authorise the directors to disapply pre-emption rights

                                                                                       31,947,121       99.99%   2,846            0.01%   7,085            31,949,967

(1)     Any proxy appointments, which gave discretion to the Chairman have
been included in the 'For' votes total.

(2)     Votes "For" and "Against" any resolution are expressed as a
percentage of votes validly cast for that resolution.

(3)     A vote "Withheld" is not a vote in law and is not counted in the
calculation of the percentage of shares voted "For" or "Against", nor in the
aggregate figure of total votes cast.

 

 

Issue of Equity and Total Voting Rights

 

Following shareholder approval at the general meeting and conditional on
admission, 67,576,000 new ordinary shares have been allotted pursuant to the
Placing, 1,147,560 new ordinary shares pursuant to the Retail Offer and
12,424,000 pursuant to the Subscription.

 

The Company has therefore allotted a total of 81,147,560 new ordinary shares
in connection with the Fundraising.

 

Admission is expected to take place at 8.00 a.m. on or around 10 January 2024.

 

Following Admission, the total number of Ordinary Shares in the capital of the
Company in issue will be 176,964,426 with each Ordinary Share carrying the
right to one vote. There are no shares held in treasury and therefore,
following Admission, the total number of voting rights in the Company will be
176,964,426.

 

The above figure may be used by Shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure, Guidance and Transparency Rules.

 

Capitalised terms used in this announcement have the meaning given to them in
the announcement of the Placing and Subscription dated 21 December 2023,
unless otherwise defined in this announcement.

 

 

For more information visit www.genincode.com (http://www.genincode.com/)

 

Enquiries:

 

 GENinCode Plc                       www.genincode.com (http://www.genincode.com/)  or via Walbrook PR
 Matthew Walls, CEO

 Paul Foulger, CFO

 Cavendish Capital Markets Limited   Tel: +44 (0)20 7220 0500
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Nigel Birks (ECM)

 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                 Tel: 020 7933 8780 or

 Anna Dunphy / Louis Ashe-Jepson /   geincode@walbrookpr.com (mailto:geincode@walbrookpr.com)

 Phillip Marriage                    Mob: +44 (0)7876 741 001 / +44 (0)7747 515 393 / +44 (0) 7867 984 082

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIEADFNEFSLEFA